Therefore, the present study aims to explore the possible reason for different prognosis between IDH1 MUT and WT GBM patients at basic research level and provide a prognostic prediction model and theoretical basis for new potential adjuvant postoperative treatment methods such as immune therapy in the future. This evidence concerns the gene IDH1 and glioblastoma.